MX2022008174A - Derivado de insulina. - Google Patents

Derivado de insulina.

Info

Publication number
MX2022008174A
MX2022008174A MX2022008174A MX2022008174A MX2022008174A MX 2022008174 A MX2022008174 A MX 2022008174A MX 2022008174 A MX2022008174 A MX 2022008174A MX 2022008174 A MX2022008174 A MX 2022008174A MX 2022008174 A MX2022008174 A MX 2022008174A
Authority
MX
Mexico
Prior art keywords
insulin
insulin derivative
pharmaceutical composition
pharmaceutical formulation
derivative
Prior art date
Application number
MX2022008174A
Other languages
English (en)
Spanish (es)
Inventor
Wei Chen
Zhongru Gan
Yining Zhang
Fangkai Xue
Lingyu Cai
Jianghong Niu
Bin Mu
Original Assignee
Gan & Lee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gan & Lee Pharmaceuticals Co Ltd filed Critical Gan & Lee Pharmaceuticals Co Ltd
Publication of MX2022008174A publication Critical patent/MX2022008174A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2022008174A 2019-12-30 2020-12-29 Derivado de insulina. MX2022008174A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911398378 2019-12-30
CN202011057926 2020-09-29
PCT/CN2020/141018 WO2021136293A1 (zh) 2019-12-30 2020-12-29 胰岛素衍生物

Publications (1)

Publication Number Publication Date
MX2022008174A true MX2022008174A (es) 2022-08-02

Family

ID=76687317

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022008174A MX2022008174A (es) 2019-12-30 2020-12-29 Derivado de insulina.
MX2022008130A MX2022008130A (es) 2019-12-30 2020-12-29 Derivado de insulina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022008130A MX2022008130A (es) 2019-12-30 2020-12-29 Derivado de insulina.

Country Status (10)

Country Link
US (5) US20240025957A1 (https=)
EP (3) EP4086280A4 (https=)
JP (3) JP2023510206A (https=)
KR (2) KR20220119730A (https=)
CN (12) CN114901683B (https=)
AU (2) AU2020417892A1 (https=)
BR (2) BR112022013009A2 (https=)
CA (2) CA3166494A1 (https=)
MX (2) MX2022008174A (https=)
WO (3) WO2021136293A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119529057A (zh) * 2019-12-30 2025-02-28 甘李药业股份有限公司 长效glp-1化合物
AU2020417892A1 (en) 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Insulin derivative
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
KR20240013778A (ko) * 2021-05-24 2024-01-30 선샤인 레이크 파르마 컴퍼니 리미티드 신규한 아실화된 인슐린 유사체
JP2024522904A (ja) * 2021-06-25 2024-06-21 ガン アンド リー ファーマシューティカルズ カンパニー リミテッド アシル化インスリンを含む医薬組成物
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN118574842A (zh) * 2022-01-28 2024-08-30 甘李药业股份有限公司 酰化胰岛素
CN120731085A (zh) * 2023-03-02 2025-09-30 甘李药业股份有限公司 一种glp-1化合物的医药用途
EP4722236A1 (en) * 2023-05-24 2026-04-08 The United Bio-Technology (Hengqin) Co., Ltd. Insulin derivative and use thereof
CN116327890B (zh) * 2023-05-29 2023-12-08 北京先为达生物科技有限公司 口服递送的组合物及其应用
CN116789801B (zh) * 2023-08-21 2023-11-14 南京赛诺生物技术有限公司 新型胰岛素衍生物及其用途
WO2025077751A1 (zh) * 2023-10-09 2025-04-17 甘李药业股份有限公司 Glp-1肽组合物及其用途
WO2025098457A1 (zh) * 2023-11-07 2025-05-15 甘李药业股份有限公司 用于降糖的酰化胰岛素
WO2025098502A1 (zh) * 2023-11-08 2025-05-15 甘李药业股份有限公司 包含胰岛素衍生物的药物组合物的治疗用途
WO2025228255A1 (zh) * 2024-04-28 2025-11-06 正大天晴药业集团股份有限公司 酰化人胰岛素类似物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199391A (en) 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK336188D0 (da) 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
CZ287945B6 (cs) 1993-09-17 2001-03-14 Novo Nordisk A/S Inzulinový derivát a farmaceutický prostředek s jeho obsahem pro léčení diabetu
AU1272295A (en) 1993-12-17 1995-07-03 Novo Nordisk A/S Proinsulin-like compounds
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
KR0150565B1 (ko) 1995-02-15 1998-08-17 김정재 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
EP0741188A3 (en) 1995-05-05 1999-07-14 Eli Lilly And Company Single chain insulin with high bioactivity
MXPA06001283A (es) 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
EP1991576B1 (en) * 2006-02-27 2010-09-29 Novo Nordisk A/S Insulin derivatives
MX2008014061A (es) 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
ES2542146T3 (es) 2006-07-31 2015-07-31 Novo Nordisk A/S Insulinas extendidas PEGiladas.
WO2009010428A1 (en) 2007-07-16 2009-01-22 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
EP2178910B1 (en) * 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
KR20100053561A (ko) * 2007-08-15 2010-05-20 노보 노르디스크 에이/에스 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체
WO2009030774A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
CN102037008B (zh) 2008-03-18 2016-08-31 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、酰化胰岛素类似物
EP2552950A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
CN103596584B (zh) * 2011-06-15 2016-12-14 诺沃—诺迪斯克有限公司 多取代的胰岛素
RU2014127270A (ru) 2011-12-15 2016-02-10 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Аналог человеческого инсулина и его ацилированное производное
US9481721B2 (en) 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
US20150111820A1 (en) * 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives
JP2017506640A (ja) 2014-02-14 2017-03-09 セントローズ， エルエルシー 細胞外標的化薬物共役体
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
CN105820233B (zh) 2015-01-04 2021-06-15 甘李药业股份有限公司 一种胰岛素衍生物的制备方法
US20180000742A1 (en) * 2015-01-29 2018-01-04 Novo Nordisk A/S Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and a Polyvinyl Alcohol Coating
MX2018002223A (es) * 2015-08-25 2018-03-23 Novo Nordisk As Derivados de insulina novedosos y usos medicos de los mismos.
US10651467B2 (en) * 2015-08-27 2020-05-12 Haldor Topsøe A/S High tap density lithium positive electrode active material, intermediate and process of preparation
JP7432361B2 (ja) 2016-08-02 2024-02-16 江蘇恒瑞医薬股▲ふん▼有限公司 ヒトインスリンまたはそのアナログのアシル化誘導体
TWI700091B (zh) 2016-12-16 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 含胰島素醫藥組成物
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
AU2020417892A1 (en) 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Insulin derivative
CN119529057A (zh) * 2019-12-30 2025-02-28 甘李药业股份有限公司 长效glp-1化合物
CN118574842A (zh) * 2022-01-28 2024-08-30 甘李药业股份有限公司 酰化胰岛素

Also Published As

Publication number Publication date
CN118420743A (zh) 2024-08-02
CN114901682B (zh) 2024-04-16
JP2023510206A (ja) 2023-03-13
EP4086279A4 (en) 2024-08-07
JP2025161829A (ja) 2025-10-24
CN118480114A (zh) 2024-08-13
CN114901683A (zh) 2022-08-12
US20250228919A1 (en) 2025-07-17
BR112022013150A2 (pt) 2023-02-28
EP4086280A1 (en) 2022-11-09
AU2020418205A1 (en) 2022-08-04
CN114901681A (zh) 2022-08-12
US20230126068A1 (en) 2023-04-27
KR20220121833A (ko) 2022-09-01
MX2022008130A (es) 2022-10-03
KR20220119730A (ko) 2022-08-30
CN114901683B (zh) 2024-09-13
CN118420744A (zh) 2024-08-02
AU2020417892A1 (en) 2022-08-25
EP4086278A4 (en) 2024-08-07
JP2023510219A (ja) 2023-03-13
CN114901682A (zh) 2022-08-12
EP4086280A4 (en) 2024-05-29
US12576136B2 (en) 2026-03-17
CN114901681B (zh) 2024-04-09
CN118894922A (zh) 2024-11-05
EP4086279A1 (en) 2022-11-09
CA3166495A1 (en) 2021-07-08
WO2021136296A1 (zh) 2021-07-08
BR112022013009A2 (pt) 2022-09-06
US20250032589A1 (en) 2025-01-30
CA3166494A1 (en) 2021-07-08
CN118598978A (zh) 2024-09-06
WO2021136302A1 (zh) 2021-07-08
CN118206632A (zh) 2024-06-18
WO2021136293A1 (zh) 2021-07-08
CN118666989A (zh) 2024-09-20
US20240025957A1 (en) 2024-01-25
EP4086278A1 (en) 2022-11-09
CN118772259A (zh) 2024-10-15
US20240239862A1 (en) 2024-07-18
CN118754967A (zh) 2024-10-11

Similar Documents

Publication Publication Date Title
MX2022008174A (es) Derivado de insulina.
ATE471144T1 (de) Intranasale verabreichung von schnell wirkendem insulin
MY192084A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
CY1120583T1 (el) Σκευασματα ινσουλινης για γρηγορη προσληψη
WO2023078333A8 (zh) 一种取代的苯丙酸衍生物及其用途
MX2020013785A (es) Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo.
ECSP13013010A (es) Preparación de gadobutrol de alta pureza
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
MY159865A (en) Aqueous insulin preparations containing methionine
ZA202406617B (en) Insulin containing pharmaceutical compositions
CY1109719T1 (el) Σκευασμα 1-[(3-υδροξυ-αδαμαντ-1-υλαμινο)-ακετυλο]-πυρρολιδινο-2-(s)-καρβονιτριλιου τροποποιημενης απελευθερωσης
EA200901155A1 (ru) Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии
HK1222297A1 (zh) 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
MX336657B (es) Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.
AR059097A1 (es) Tratamiento a largo plazo de la infeccion por vih
FI3229828T3 (fi) Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio
WO2023129956A3 (en) Dimethyltryptamine analogues as nitric oxide delivery drugs
AR046210A1 (es) Preparacion solida
PL2004235T3 (pl) Kompozycja do zastosowania kosmetycznego lub farmaceutyczno-dermatologicznego
MX2022006489A (es) Derivado de anillo de piridina fusionado, metodo de preparacion y usos farmaceuticos del mismo.
EP4088731A4 (en) COMPOSITION WITH PEPTIDE OR PEPTIDE COMPOUND AS AN ACTIVE INGREDIENT AND MEDICAL USE THEREOF
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
MX339367B (es) Composicion para tratar tuberculosis en base a perclorato de 4-tioureido-iminometilpiridinio: metodo de preparacion y tratamiento.
CY1125336T1 (el) Μια φαρμακευτικη συνθεση ξηρης σκονης για εισπνοη που περιλαμβανει μια θυρεοειδικη ορμονη